Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs iShares 1 3 Year Treasury Bond ETF (SHY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs iShares 1 3 Year Treasury Bond ETF — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.59 (market cap $12.58B), while iShares 1 3 Year Treasury Bond ETF trades at $81.19 (market cap $26.68B). The key difference: iShares 1 3 Year Treasury Bond ETF is far larger — about 2.1× Halozyme Therapeutics Inc. Common Stock's market cap, and Halozyme Therapeutics Inc. Common Stock is trading nearer its 52-week high, iShares 1 3 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and iShares 1 3 Year Treasury Bond ETF for 63 Days on average.
| HALO | SHY | |
|---|---|---|
Market Cap | $12.58B | $26.68B |
Volume | 2,179,278 | 4,077,691 |
Sector | Health | Fixed Income |
52-Week High | $115.22 | $83.18 |
52-Week Low | $61.63 | $81.05 |
Typical Hold Time | 1 Days | 63 Days |
Enterprise Value | $14.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SHY trades at $81.20 with minimal daily movement (+0.05%), showing stability amid broader bond market volatility. Technical indicators signal a bearish trend with moving averages pointing downward, though oscillators remain neutral. Recent dividend payments of $0.24-$0.25 per share provide consistent income, but key financial ratios are unavailable for fundamental assessment. The ETF faces headwinds from rising Treasury yields and persistent inflation pressures affecting fixed income markets.
Outlook remains cautious as SHY navigates a challenging interest rate environment. The fund benefits from short-duration focus during Fed tightening cycles but faces pressure from bond market selloffs. Investment opportunity lies in yield advantage over cash, while risks include further rate hikes and prolonged inflation. Institutional sentiment appears mixed given conflicting technical signals and macroeconomic uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About iShares 1 3 Year Treasury Bond ETF
SHY provides exposure to U.S. Treasury bonds with remaining maturities between one and three years. It is a low-risk, highly liquid ETF designed for capital preservation and short-term income, featuring 2026 top holdings across various Treasury Notes.
Read more on SHY →
